Financial Performance - The company's operating revenue for Q1 2024 was ¥238,622,168.70, representing a decrease of 10.69% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥7,133,561.76, down 22.65% year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 32.21% to ¥6,641,379.02[5]. - The company reported a net profit margin of 6.2% for Q1 2024, down from 8.5% in Q1 2023, indicating a decline in profitability[19]. - In Q1 2024, the company's net profit was CNY 7,015,684.50, a decrease of 23.0% compared to CNY 9,111,154.02 in Q1 2023[20]. - The company's operating profit decreased to CNY 10,181,445.42, down 28.3% from CNY 14,184,102.03 in Q1 2023[20]. - The company reported a total comprehensive income of CNY 6,487,291.24, down from CNY 7,207,989.32 in the same quarter last year[21]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥52,712,185.37, indicating a significant cash outflow[5]. - The net cash flow from operating activities was negative at CNY -52,712,185.37, an improvement from CNY -113,986,510.74 in Q1 2023[23]. - The company's current assets as of March 31, 2024, totaled RMB 1,270,798,589.03, an increase from RMB 1,254,796,468.80 as of December 31, 2023[15]. - Total assets at the end of the reporting period were ¥1,471,622,094.86, a slight increase of 0.70% from the end of the previous year[6]. - The company's total assets reached RMB 1,471,622,094.86 as of March 31, 2024, compared to RMB 1,461,406,215.62 at the end of 2023[17]. - Cash and cash equivalents at the end of the period were CNY 184,501,765.10, a decrease from CNY 228,813,378.42 at the end of Q1 2023[24]. Shareholder Information - Basic earnings per share remained at ¥0.02, with diluted earnings per share also at ¥0.02[6]. - The company’s basic and diluted earnings per share remained stable at CNY 0.02 for both Q1 2024 and Q1 2023[21]. - Shareholders' equity attributable to the parent company was ¥1,173,410,600.83, reflecting a 0.57% increase from the previous year[6]. Expenses and Liabilities - Total operating costs for Q1 2024 were RMB 223,741,990.22, down 9.8% from RMB 248,127,074.01 in Q1 2023[19]. - Research and development expenses increased to CNY 915,002.70, up 48.6% from CNY 616,123.18 in the previous year[20]. - Total liabilities as of March 31, 2024, were RMB 296,223,136.82, slightly up from RMB 292,494,548.82 at the end of 2023[17]. - Non-current liabilities decreased to RMB 5,659,017.44 from RMB 6,766,920.04, a reduction of 16.4%[17]. - Financial expenses showed a decrease, with interest expenses at CNY 1,130,985.73, down from CNY 1,400,022.09 in Q1 2023[20]. Revenue Decline Factors - The decline in revenue was primarily due to a decrease in customer reagent purchases and increased R&D and business expansion expenses[8].

合富（中国）医疗科技股份有限公司 证券简称：合富中国 证券代码：603122 合富（中国）医疗科技股份有限公司 2023 年年度股东大会 会议资料 2024 年 4 月 29 日 | 2023 年年度股东大会会议须知 | | | | 2 | | --- | --- | --- | --- | --- | | 2023 年年度股东大会会议议程 | | | | 3 | | 2023 年年度股东大会会议议案 | | | | 5 | | 议案一：《关于公司 | 2023 | 年度董事会工作报告的议案》 | 5 | | | 议案二：《关于公司 | 2023 | 年度独立董事述职报告的议案》 | 12 | | | 议案三：《关于公司 | 2023 | 年度监事会工作报告的议案》 | 13 | | | 议案四：《关于公司 | 2023 | 年年度报告及其摘要的议案》 | 17 | | | 议案五：《关于公司 | 2023 | 年度财务决算报告的议案》 | 18 | | | 议案六：《关于公司 | 2023 | 年度利润分配预案的议案》 | 22 | | | 议案七：《关于续聘 | 2024 | 年度审计机构的议案》 | 2 ...

合富（中国）医疗科技股份有限公司（以下简称"公司"）于 2024 年 04 月 19 日（星期五）11:30-12:30 在价值在线网站（https://www.ir-online.cn/） 通过网络文字互动的形式召开了公司 2023 年年度业绩说明会，现将具体情况公 告如下： 一、本次业绩说明会召开情况 公司于 2024 年 04 月 19 日（星期五）11:30-12:30 召开了公司 2023 年年度 业绩说明会，董事长 李惇先生、董事 总经理 财务总监（暂代）王琼芝女士、 独立董事 Stanley Yi Chang 先生、独立董事 周露露女士、董事 杨毓莹女士、 董事会秘书 陈烨女士、投资者关系 徐晨铭女士出席了本次业绩说明会，与投资 者进行网络互动交流和沟通。本次业绩说明会召开前，公司已通过公司投资者关 系邮箱 ir_cowealth@cowealth.com 进行了提问预征集。 二、投资者提问及公司回复情况 证券代码：603122 证券简称：合富中国 公告编号：临 2024-017 合富（中国）医疗科技股份有限公司 关于 2023 年年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内 ...

合富（中国）医疗科技股份有限公司（以下简称"公司"）已于 2024 年 3 月 23 日在上海证券交易所网站（www.sse.com.cn）披露了《2023 年年度报告》及 《2023 年年度报告摘要》，为便于广大投资者更全面深入地了解公司 2023 年年 度经营成果、财务状况等，公司计划于 2024 年 04 月 19 日（星期五）11:30-12:30 举办合富（中国）医疗科技股份有限公司 2023 年年度业绩说明会，就投资者关 会议召开时间：2024 年 04 月 19 日（星期五）11:30-12:30 会议召开地点：网络平台在线交流 会议召开方式：网络文字互动 会议问题征集：投资者可于 2024 年 04 月 16 日（星期二）15:00 前，将 需要了解的情况和有关问题预先通过电子邮件的形式发送至公司投资者 关 系 邮 箱 ： ir_cowealth@cowealth.com ， 也 可 通 过 访 问 网 址 https://eseb.cn/1doSol6fypy 或使用微信扫描下方小程序码进行会前 提问。公司将通过本次业绩说明会，在信息披露允许范围内就投资者普 遍关注的问题进行回答。 重要提示 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2024-015 合富（中国）医疗科技股份有限公司 2024 年 1-3 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买卖 中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收入数 据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海证券交 易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、《证券日 报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司营业收入。 本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据以公司定期报 告为准，敬请投资者注意投资风险。 公司 2024 年 1-3 月累计合并营业收入为人民币 23,862.22 万元，较去年同 期的合并营业收入减少 10.69%。 特此公告。 合富（中国）医疗科技股份有限公司 ...

海通证券股份有限公司 关于合富（中国）医疗科技股份有限公司 2023 年度持续督导现场检查报告 上海证券交易所： 经中国证券监督管理委员会《关于核准合富（中国）医疗科技股份有限公 司首次公开发行股票的批复》（证监许可〔2021〕4074 号）批复，合富（中国） 医疗科技股份有限公司（以下简称"合富中国"、"上市公司"、"公司"）首次公 开发行股票 9,951.32 万股，每股面值人民币 1 元，每股发行价格人民币 4.19 元， 募集资金总额为人民币 416,960,308.00 元，扣除发行费用后，实际募集资金净额 为人民币 359,690,993.41 元。本次发行证券已于 2022 年 2 月 16 日在上海证券交 易所上市。海通证券股份有限公司（以下简称"海通证券"、"保荐机构"）担任 其持续督导保荐机构，持续督导期间为 2022 年 2 月 16 日至 2024 年 12 月 31 日。 （二）保荐代表人 冯超、陈邦羽 （三）现场检查时间 2024 年 3 月 21 日至 2024 年 3 月 22 日 1 （四）现场检查人员 冯超、程天鹏 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上 ...

| 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：合富中国 | | --- | --- | | 保荐代表人姓名：冯超、陈邦羽 | 被保荐公司代码：603122 | 经中国证券监督管理委员会《关于核准合富（中国）医疗科技股份有限公司 首次公开发行股票的批复》（证监许可[2021]4074 号）批复，合富（中国）医疗 科技股份有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发行股 票 99,513,200 股，每股面值人民币 1 元，每股发行价格人民币 4.19 元，募集资 金总额为人民币 416,960,308.00 元，扣除发行费用后，实际募集资金净额为人民 币 359,690,993.41 元。本次发行证券已于 2022 年 2 月 16 日在上海证券交易所上 市。海通证券股份有限公司（以下简称"保荐机构"或"海通证券"）担任其持续 督导保荐机构，持续督导期间为 2022 年 2 月 16 日至 2024 年 12 月 31 日。 在 2022 年 2 月 16 日至 2024 年 12 月 31 日持续督导期内（以下简称"本持 续督导期间"），保荐机构及保荐代表人按照《证券发行上市 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥1.09 billion, a decrease of 14.62% compared to ¥1.28 billion in 2022[24]. - Net profit attributable to shareholders decreased by 42.96% to approximately ¥47.19 million in 2023 from ¥82.72 million in 2022[24]. - Basic earnings per share fell by 45.45% to ¥0.12 in 2023, down from ¥0.22 in 2022[24]. - The weighted average return on equity decreased by 3.50 percentage points to 4.06% in 2023 from 7.56% in 2022[24]. - The total revenue for the year reached ¥1,092,272,353.17, representing a year-on-year increase of 20.70%[59]. - The operating income from the medical product circulation segment decreased significantly by 72.13% year-on-year, amounting to ¥57,426,153.35[59]. - The gross profit margin for the medical product circulation segment was reported at 26.55%, down by 12.23 percentage points compared to the previous year[59]. - The company reported a total revenue of 1,092,602,026.63 RMB for the reporting period, a decrease of 14.62% compared to the previous year[54]. - The net profit attributable to shareholders was 47,186,900 RMB, reflecting a significant decline of 42.96% year-over-year[54]. Cash Flow and Assets - The net cash flow from operating activities improved to approximately ¥11.28 million in 2023, compared to a negative cash flow of ¥30.37 million in 2022[24]. - The total assets at the end of 2023 were approximately ¥1.46 billion, a decrease of 6.26% from ¥1.56 billion at the end of 2022[24]. - The net assets attributable to shareholders at the end of 2023 were approximately ¥1.17 billion, a slight decrease of 0.93% from ¥1.18 billion at the end of 2022[24]. - The total operating costs for the year were ¥866,158,543.42, a reduction from ¥1,021,774,257.93 in the previous year[63]. - The net cash flow from operating activities was ¥11,281,136.90, a significant improvement from a negative cash flow of ¥30,366,164.41 in the same period last year[75]. Strategic Initiatives and Future Outlook - The company aims to achieve approximately CNY 1.248 billion in revenue and a net profit of around CNY 79 million for the year 2024[96]. - The company plans to enhance customer loyalty by providing differentiated empowerment services and expanding its customer base[96]. - The company will focus on expanding its marketing network nationwide, particularly in regions where it has not yet established operations[92]. - The company is committed to optimizing and upgrading its centralized procurement services for in vitro diagnostic reagents and consumables[91]. - The company plans to enhance its digital marketing efforts, allocating an additional 2 million to boost online presence and engagement[113]. Corporate Governance and Compliance - The company has established a complete independent financial accounting system and internal control measures, ensuring financial independence from the controlling shareholder[106]. - The company has received a standard unqualified opinion on the effectiveness of its internal control from KPMG Huazhen, indicating robust internal control practices[146]. - The company has not experienced any major legal violations or penalties during the reporting period[105]. - The company has established an independent organizational structure, ensuring that the shareholders' meeting, board of directors, and supervisory board operate independently without interference from controlling shareholders[107]. - The company has no actual controller, leading to potential instability in governance and operational decision-making risks[98]. Social Responsibility and Community Engagement - The company has actively engaged in social responsibility initiatives, with total donations amounting to ¥90.13 million, including ¥52.87 million in cash and ¥37.26 million in material contributions[155]. - The company committed to supporting national poverty alleviation and rural revitalization efforts, donating ¥60,000 to improve educational opportunities for underprivileged youth[156]. - The company donated medical clinical testing equipment and reagents to 8 hospitals in Guanghe County, benefiting approximately 200-500 patients[157]. - The company aims to continue leveraging its resources to support social welfare and rural revitalization as part of its corporate social responsibility[157]. Research and Development - Research and development expenses increased by 13.70% to 3,182,530.27 RMB, indicating a focus on innovation and new product development[55]. - The company is investing heavily in R&D for new technologies, with a budget allocation of 10 million for the upcoming year[113]. - The company has 9 R&D personnel, accounting for 3.75% of the total workforce, with 1 holding a master's degree and 8 holding bachelor's degrees[71]. Shareholder Matters and Dividends - The board proposed a cash dividend of CNY 0.60 per share, totaling approximately CNY 23.88 million, pending shareholder approval[6]. - The company has a cash dividend policy that stipulates a minimum of 10% of the distributable profit will be distributed as cash dividends if conditions are met[135]. - The total dividend amount (including tax) is ¥23,883,157.98, which also represents 50.61% of the consolidated net profit attributable to ordinary shareholders[142]. - The company’s profit distribution plan requires a two-thirds majority approval from shareholders at the general meeting[137].

Financial Performance - Revenue for the reporting period was RMB 1,092.60 million, a decrease of 14.62% year-on-year[8] - Net profit attributable to shareholders of the listed company was RMB 47.19 million, a decrease of 42.96% year-on-year[8] - Revenue for the third quarter was RMB 267.93 million, with a net profit attributable to shareholders of RMB 13.15 million[6] - Total assets decreased by 6.26% to 1,461,406,215.62 in 2023 compared to 1,559,065,109.86 in 2022[22] - Revenue declined by 14.62% to 1,092,602,026.63 in 2023 from 1,279,666,218.81 in 2022[22] - Net profit attributable to shareholders dropped by 42.96% to 47,186,921.09 in 2023 from 82,719,667.82 in 2022[22] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 38.18% to 46,919,175.91 in 2023 from 75,895,588.47 in 2022[22] - Weighted average return on equity decreased by 3.50 percentage points to 4.06% in 2023 from 7.56% in 2022[22] - Basic earnings per share fell by 45.45% to 0.12 in 2023 from 0.22 in 2022[22] - Diluted earnings per share also decreased by 45.45% to 0.12 in 2023 from 0.22 in 2022[22] Cash Flow and Shareholder Information - Operating cash flow for the reporting period was RMB 11.28 million, an increase of RMB 41.65 million compared to the same period last year[8] - The company's operating cash flow turned positive in the second quarter and continued to be positive in the third quarter[1] - The number of ordinary shareholders at the end of the reporting period was 35,311, a decrease from 36,341 at the end of the previous month[3] - The largest shareholder, Hefu (Hong Kong) Holdings Limited, holds 55.00% of the company's shares[3] - Operating cash flow turned positive to 11,281,136.90 in 2023 from -30,366,164.41 in 2022[22] Strategic Adjustments and Business Focus - The company has reduced non-terminal medical product distribution business to focus on strategic adjustments and risk control[1] - The company has established a talent team to promote empowerment projects and increase customer stickiness[1] - The company is focusing on technological innovation and service capabilities to meet the increasing demands of the market[12][13] - The company signed medium and long-term contracts with medical institutions, covering 4 new provinces and adding over 20 new terminal customers[14] - The company's medical product distribution business focuses on sales and maintenance of radiotherapy equipment, as well as sales of immunodiagnostic and biochemical diagnostic equipment[14] - The company's hospital empowerment platform includes services such as key specialty co-construction, group hospital strategic planning, and clinical innovation research collaboration[21] - The company's integrated business platform provides value-added services to medical institutions, including unified procurement, distribution, and inventory management of reagents and consumables[14] Market and Industry Trends - The domestic in vitro diagnostics market has exceeded RMB 100 billion and is expected to continue growing due to increased health awareness and aging population[18] Technological Innovation and Product Development - The company launched a decision analysis integrated platform, with over 10 medical institutions deciding to adopt it by year-end[21] - The company's subsidiary, Heyi Information, will localize production of the surgical audio-visual imaging chain integration platform "Metaway" in mainland China[21] - The company collaborated with Zhejiang University's Computer Innovation Technology Institute to develop a clinical diagnostic assistance system using AI and big data analysis[21] Cross-Strait Collaboration and Resource Sharing - The company facilitated cross-strait medical resource sharing, assisting mainland medical institutions in training in Taiwan and introducing Taiwanese experts to mainland hospitals[14] Dividend Proposal - The company proposed a cash dividend of RMB 0.60 per 10 shares, totaling RMB 23,883,157.98 (tax included), pending shareholder approval[16]

合富（中国）医疗科技股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603122 证券简称：合富中国 公告编号：临 2024-013 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2024 年 4 月 29 日 14 点 30 分 召开地点：上海市徐汇区虹漕路 456 号光启大楼 20 楼会议室 (五) 网络投票的系统、起止日期和投票时间。 重要内容提示： 一、召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 (二) 股东大会召集人：董事会 股东大会召开日期：2024年4月29日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 4 月 29 日 至 2024 年 4 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间 ...